Table 1 Baseline and end of study characteristics of the study population
Baseline | End of study | |||||
|---|---|---|---|---|---|---|
Placebo (n = 74) | Supplemented (n = 74) | p-value | Placebo (n = 74) | Supplemented (n = 74) | p-value | |
Age (months) | 35.2 ± 20 | 37.9 ± 20 | 0.72 | - | - | - |
Sex | - | |||||
Female | 45.9% | 48.6% | 0.74 | - | - | - |
Antecedent | ||||||
Reported children with fever episode on the previous year‡ | 78.30 (69–87.6) | 89.20 (82.1–96.3) | 0.041 | - | - | - |
Reported children with mosquito-net use on the previous night | 52.7 (41.4–64.0) | 56.7 (45.4–68.0) | 0.62 | - | - | - |
Anthropometry | ||||||
Weight-for-height Z- score <-2.0 | -0.73 ± 2.8 | -0.82 ± 1.4 | 0.58 | -1.10 ± 2 | -1.03 ± 1.3 | 0.80 |
Height-for-age Z- score <-2.0 | -1.60 ± 2.3 | -1.50 ± 2.0 | 0.77 | -1.5 ± 2.4 | -1.49 ± 1.7 | 0.97 |
Weight-for-height Z- score <-2.0 (%) | 20.3 (11.2–29.4) | 13.5 (5.7–21.3) | 0.20 | 27.0 (17.0–37.0) | 23.0 (13.5–32.5) | 0.56 |
Height-for-age Z- score <-2.0 (%) | 47.3 (36.0–58.6) | 40.5 (29.3–51.7) | 0.40 | 46.0 (34.7–57.3) | 35.0 (24.2–45.8) | 0.20 |
Hematology | ||||||
Mean (SD) hemoglobin (g/dl) | 9.4 ± 1.6 | 9.31 ± 2.3 | 0.75 | 10.21 ± 1.82 | 10.09 ± 1.97 | 0.70 |
Anemia ≤ 7.0 g/dl‡ (%) | 5.4 (0.4–10.5) | 18.0 (9.3–26.7) | 0.020 | 5.4 (0.4–10.5) | 5.4 (0.4–10.5) | 0.71 |
Malariometric indices | ||||||
Positive P. falciparum | 61.0 (51–72) | 76.0 (66.-85) | 0.052 | 57.5% (46.2–68.8) | 42.0% (32.8–55.2) | 0.048 |
Geometric mean density P. falciparum positive asexual forms/μl | 1444 (923–2259) | 1589 (1026–2459) | 0.38 | 1945 (1155–3275) | 1011 (647–1579) | 0.85 |
Enlarged spleen | 61.0% (51–72) | 58.0% (47–69) | 0.73 | 57.0% (46–68) | 53.0% (42–64) | 0.62 |